Chinese language lesson scores

increases

the scores of Chinese language lesson in the Hup group were elevated markedly too

PMID 10678121 · one of two readings recorded this

memory quotient (MQ) and Chinese language lesson scores, huperzine-A capsules 50 micrograms twice daily for 4 weeks versus placebo, matched adolescent students

increases, MQ 115 +/- 6 in huperzine-A group versus 104 +/- 9 in placebo group, n = 68

Not recorded as a finding: this platform holds no node for the endpoint

At the end of trial, the Hup group's MQ (115 +/- 6) was more than that of the placebo group (104 +/- 9, P < 0.01), and the scores of Chinese language lesson in the Hup group were elevated markedly too.

PMID 10678121 · one of two readings recorded this

memory quotient (MQ) in adolescent students, huperzine-A capsules 2 x 50 micrograms b.i.d. versus placebo for 4 weeks

increases, MQ 115 +/- 6 versus 104 +/- 9

Not recorded as a finding: this platform holds no node for the endpoint

At the end of trial, the Hup group's MQ (115 +/- 6) was more than that of the placebo group (104 +/- 9, P < 0.01), and the scores of Chinese language lesson in the Hup group were elevated markedly too.

PMID 10678121 · one of two readings recorded this

memory quotient

increases, p = 0.01

At the end of trial, the Hup group's MQ (115 +/- 6) was more than that of the placebo group (104 +/- 9, P < 0.01)

PMID 10678121 · one of two readings recorded this

all psychological evaluations, before versus after

unclear, p = 0.01

There were significant differences (P < 0.01) on all the psychological evaluations between 'before' and 'after' the 60-d trial of 2 groups

PMID 10678137 · one of two readings recorded this

oxygen free radicals

unclear

The changes of oxygen free radicals in 2 groups showed marked improvement

PMID 10678137 · one of two readings recorded this

psychological evaluations, capsule group versus tablet group

no effect, p = 0.05

there was no significant difference between 2 groups by group t test (P > 0.05)

PMID 10678137 · one of two readings recorded this

psychological rating scales and plasma and erythrocyte oxygen free radicals, huperzine-A capsules versus huperzine-A tablets, 50 micrograms units, four units twice a day for 60 days

no effect, no significant difference between capsule and tablet groups, n = 60

Not recorded as a finding: the comparison was against another active treatment

There were significant differences (P < 0.01) on all the psychological evaluations between 'before' and 'after' the 60-d trial of 2 groups, but there was no significant difference between 2 groups by group t test (P > 0.05).

PMID 10678137 · one of two readings recorded this

psychological rating scales in Alzheimer disease, huperzine-A capsules versus huperzine-A tablets, 50 micrograms units, 60 days

no effect, no significant difference between the capsule and tablet groups

Not recorded as a finding: the comparison was against another active treatment

There were significant differences (P < 0.01) on all the psychological evaluations between 'before' and 'after' the 60-d trial of 2 groups, but there was no significant difference between 2 groups by group t test (P > 0.05).

PMID 10678137 · one of two readings recorded this

activity of daily life improvement from baseline

unclear, p = 0.001

an improvement of 2.4 points by ADL (P = 0.001)

PMID 12181083 · one of two readings recorded this

behavior and mood improvement from baseline

unclear, p = 0.008

an improvement of 1.5 points in behavior and mood by ADAS-non-Cog (P = 0.008)

PMID 12181083 · one of two readings recorded this

clinical improvement, proportion of patients on the mend

increases

with 59.2% of the patients being on the mend clinically

PMID 12181083 · one of two readings recorded this

cognition improvement from baseline

unclear

there was an improvement of 4.6 points in cognition assessed by ADAS-Cog (P = 0.000)

PMID 12181083 · one of two readings recorded this

proportion of patients improving by 4 or more points on ADAS-Cog, huperzine Alpha 400 microg/day versus placebo for 12 weeks

increases, 56.1% versus 12.5% (huperzine Alpha versus placebo)

Not recorded as a finding: a node exists but the paper states a different instrument or population

The proportions of patients with an improvement of >/= 4 points by ADAS-Cog were 56.1% and 12.5% in the huperzine Alpha group and placebo group respectively (P = 0.000).

PMID 12181083 · one of two readings recorded this

proportion of patients with at least a 4-point improvement on ADAS-Cog, huperzine Alpha 400 micro g/day versus placebo for 12 weeks

increases, 56.1% versus 12.5% of patients

Not recorded as a finding: a node exists but the paper states a different instrument or population

The proportions of patients with an improvement of >/= 4 points by ADAS-Cog were 56.1% and 12.5% in the huperzine Alpha group and placebo group respectively (P = 0.000).

PMID 12181083 · one of two readings recorded this

proportion scoring 1 approximately 2 points

unclear

70% of the patients in huperzine Alpha group scored 1 approximately 3 points, and 27.8% of them scored 1 approximately 2 points by CIBIC-plus

PMID 12181083 · one of two readings recorded this

proportion scoring 1 approximately 3 points

unclear

70% of the patients in huperzine Alpha group scored 1 approximately 3 points, and 27.8% of them scored 1 approximately 2 points by CIBIC-plus

PMID 12181083 · one of two readings recorded this

proportion with ADL improved by at least 10%

increases

with the capacity of ADL improved by at least 10% among 32.75% of the patients

PMID 12181083 · one of two readings recorded this

proportion with improvement of > 0 points

increases

The proportions of patients with an improvement of > 0 points by ADS-non-C0g were 70.0% and 36.3% in the huperzine Alpha group and placebo group respectively (P = 0.000)

PMID 12181083 · one of two readings recorded this

proportion with improvement of 1 approximately 3 points in global rating

increases, p = 0.01

The proportions of patients with an improvement of 1 approximately 3 points in global rating by CIBIC-plus were 59.2% and 40.6% in the huperzine Alpha group and placebo group respectively (P = 0.01)

PMID 12181083 · one of two readings recorded this

proportion with improvement of >/= 10% points

increases, p = 0.01

The proportions of patients with an improvement of >/= 10% points by ADL were 32.7% and 17.2% in the huperzine Alpha group and placebo group respectively (P = 0.01)

PMID 12181083 · one of two readings recorded this

proportion with improvement of >/= 4 points

increases

The proportions of patients with an improvement of >/= 4 points by ADAS-Cog were 56.1% and 12.5% in the huperzine Alpha group and placebo group respectively (P = 0.000)

PMID 12181083 · one of two readings recorded this

CSF acetylcholine concentration, T2 versus T1

decreases, p = 0.01

In both the groups, Ach concentration in the CSF were lower at T2 than that at T1 (P<0.01)

PMID 17121726 · one of two readings recorded this

CSF acetylcholine concentration, T2 versus T1

decreases, p = 0.01

In both the groups, Ach concentration in the CSF were lower at T2 than that at T1 (P<0.01)

PMID 17121726 · one of two readings recorded this

CSF acetylcholine concentration

increases, p = 0.01

at T2, CSF Ach concentration was significantly higher in group I than in group II (P<0.01)

PMID 17121726 · one of two readings recorded this

CSF cholinesterase activity at T2

decreases, p = 0.01

in group I, the activity of CSF ChE at T2 was lower than that at T1 (P<0.01), and also lower than at T2 in group II (P<0.01)

PMID 17121726 · one of two readings recorded this

CSF cholinesterase activity, T2 versus T1

decreases, p = 0.01

in group I, the activity of CSF ChE at T2 was lower than that at T1 (P<0.01), and also lower than at T2 in group II (P<0.01)

PMID 17121726 · one of two readings recorded this

curative effect

increases

The result showed that the curative effect of huperzine A was significant

PMID 1781288 · one of two readings recorded this

memory on the Wechsler memory scale, huperzine A im 0.05 mg bid for 4 weeks (multi-infarct or senile dementia) or 0.03 mg bid for 2 weeks (simple memory disorders) versus saline

increases, curative effect of huperzine A significant, n = 160

Not recorded as a finding: this platform holds no node for the endpoint

The result showed that the curative effect of huperzine A was significant.

PMID 1781288 · one of two readings recorded this

memory on the Wechsler memory scale, huperzine A im 0.05 mg bid for 4 wk (multi-infarct dementia) or 0.03 mg bid for 2 wk (simple memory disorders) versus saline

increases, curative effect described as significant, no figures

Not recorded as a finding: this platform holds no node for the endpoint

The result showed that the curative effect of huperzine A was significant.

PMID 1781288 · one of two readings recorded this

behavioral disturbance, ADAS-non-Cog at 12 weeks (huperzine A versus placebo)

decreases

at 12 weeks (WMD -1.52, 95% CI-2.39 to -0.65)

PMID 18425924 · one of two readings recorded this

behavioral disturbance, ADAS-non-Cog at six weeks (huperzine A versus placebo)

decreases

behavioral disturbance measured by ADAS-non-Cog at six weeks (WMD -1.33, 95%CI -2.12 to -0.54)

PMID 18425924 · one of two readings recorded this

functional performance, ADL (huperzine A versus placebo)

decreases, p = 0.00001

functional performance measured by ADL (WMD = -7.17; 95% CI -9.13 to -5.22; P < 0.00001)

PMID 18425924 · one of two readings recorded this

general cognitive function, ADAS-Cog at 12 weeks (huperzine A versus placebo)

increases

at 12 weeks (WMD 2.51; 95% CI 1.74 to 3.28)

PMID 18425924 · one of two readings recorded this

general cognitive function, ADAS-Cog at six weeks (huperzine A versus placebo)

increases

ADAS-Cog at six weeks (WMD 1.91; 95% CI 1.27 to 2.55)

PMID 18425924 · one of two readings recorded this

general cognitive function, HDS (huperzine A versus placebo)

no effect, p = 0.06

general cognitive function measured by Hasegawa Dementia Scale (HDS) (WMD: 2.78; 95% CI -0.17 to 5.73, P = 0.06)

PMID 18425924 · one of two readings recorded this

general cognitive function, MMSE (huperzine A versus placebo)

increases, p = 0.00001

general cognitive function measured by MMSE (WMD 2.81; 95% CI 1.87 to 3.76; P < 0.00001)

PMID 18425924 · one of two readings recorded this

global clinical assessment, CDR (huperzine A versus placebo)

decreases

global clinical assessment measured by CDR (WMD -0.80; 95% CI -0.95 to -0.65)

PMID 18425924 · one of two readings recorded this

global clinical assessment, CIBIC-plus (huperzine A versus placebo)

increases

CIBIC-plus (OR 4.32, 95% CI 2.37 to 7.90)

PMID 18425924 · one of two readings recorded this

specific cognitive function, WMS (huperzine A versus placebo)

no effect, p = 0.19

specific cognitive function measured by Weshler Memory Scale (WMS) (WMD = 6.64; 95% CI -3.22 to 16.50; P = 0.19)

PMID 18425924 · one of two readings recorded this

plasma butyrylcholinesterase activity

no effect

Plasma BChE was unaffected by huperzine A treatment

PMID 18572153 · one of two readings recorded this

red blood cell acetylcholinesterase inhibition, WRAIR whole blood cholinesterase assay

decreases, 30-40% inhibition after 100 microg to more than 50% at 400 microg, n = 12

Not recorded as a finding: no outcome node for RBC AChE inhibition; the result sentence also does not name huperzine A

Significant inhibition of AChE was observed, ranging from 30-40% after 100 microg to >50% at 400 microg, and peaking 1.5h after the last dose.

PMID 18572153 · both readings recorded this

red blood cell AChE activity after ex vivo soman exposure and spin-column removal

increases

Huperzine A-inhibited red blood cell (RBC) AChE activity was restored almost to the level that was initially inhibited by the drug

PMID 18572153 · one of two readings recorded this

red blood cell AChE activity, recovery

decreases

even 48 h after the last dose red blood cell AChE was about 10% below control (pre-dose) values

PMID 18572153 · one of two readings recorded this

red blood cell AChE inhibition, peak

decreases

Significant inhibition of AChE was observed, ranging from 30-40% after 100 microg to >50% at 400 microg, and peaking 1.5h after the last dose

PMID 18572153 · one of two readings recorded this

red blood cell AChE inhibition

decreases

Significant inhibition of AChE was observed, ranging from 30-40% after 100 microg to >50% at 400 microg, and peaking 1.5h after the last dose

PMID 18572153 · one of two readings recorded this

activities of daily living scale, ADL (HupA versus placebo)

increases

Oral administration of HupA for 8-24 weeks (300-500 microg daily) led to significant improvements in MMSE and ADL

PMID 19221692 · one of two readings recorded this

activities of daily living scale (ADL), huperzine A versus placebo

Not recorded as a finding: The ADL scale is not named beyond ADL and its direction of improvement (score up or down) is not stated, so the score direction cannot be recorded

Oral administration of HupA for 8-24 weeks (300-500 microg daily) led to significant improvements in MMSE and ADL.

PMID 19221692 · one of two readings recorded this

ADL effect size over treatment time (meta-regression)

increases

The results of meta-regression showed that the estimated effect size of MMSE and ADL was increased over the treatment time

PMID 19221692 · one of two readings recorded this

mini-mental state examination, MMSE (HupA versus placebo)

increases

Oral administration of HupA for 8-24 weeks (300-500 microg daily) led to significant improvements in MMSE and ADL

PMID 19221692 · one of two readings recorded this

MMSE effect size over treatment time (meta-regression)

increases

The results of meta-regression showed that the estimated effect size of MMSE and ADL was increased over the treatment time

PMID 19221692 · one of two readings recorded this

cognitive function

no effect, n = 14

No significant beneficial effect of Huperzine A on the improvement of cognitive function measured by MMSE for VaD (WMD 2.40; 95% CI -4.78 to 9.58) was observed

PMID 19370686 · one of two readings recorded this

death from all causes

no effect

No death from all causes at the end of treatment were reported

PMID 19370686 · one of two readings recorded this

activities of daily living

no effect

Changes in clinical global impression of change, NPI, and activities of daily living were not significant at either dose

PMID 21502597 · one of two readings recorded this

ADAS-Cog change, huperzine A 400 μg BID versus placebo at 11 and 16 weeks

increases, week 16: 1.92-point improvement vs 0.34-point improvement in placebo, p = 0.07

Not recorded as a finding: The only sentence mixes a significant week-11 result with a non-significant week-16 result and runs near the cap, so neither timepoint can be anchored alone

In secondary analyses, huperzine A 400 μg BID showed a 2.27-point improvement in ADAS-Cog at 11 weeks vs 0.29-point decline in the placebo group (p = 0.001), and a 1.92-point improvement vs 0.34-point improvement in the placebo arm (p = 0.07) at week 16.

PMID 21502597 · one of two readings recorded this

ADAS-Cog change, huperzine A 400 μg BID versus placebo, at weeks 11 and 16

1.92-point improvement vs 0.34-point improvement in the placebo arm at week 16, p = 0.07

Not recorded as a finding: Secondary analysis; the sentence mixes weeks 11 and 16, and the week-16 difference is not significant with no absence stated in words

In secondary analyses, huperzine A 400 μg BID showed a 2.27-point improvement in ADAS-Cog at 11 weeks vs 0.29-point decline in the placebo group (p = 0.001), and a 1.92-point improvement vs 0.34-point improvement in the placebo arm (p = 0.07) at week 16.

PMID 21502597 · one of two readings recorded this

change in ADAS-Cog, huperzine A 200 μg BID versus placebo (primary analysis)

no effect

Huperzine A 200 μg BID did not influence change in ADAS-Cog at 16 weeks

PMID 21502597 · one of two readings recorded this

change in ADAS-Cog, huperzine A 400 μg BID (improvement) versus placebo (decline)

increases, p = 0.001

huperzine A 400 μg BID showed a 2.27-point improvement in ADAS-Cog at 11 weeks vs 0.29-point decline in the placebo group (p = 0.001)

PMID 21502597 · one of two readings recorded this

change in ADAS-Cog, huperzine A 400 μg BID (improvement) versus placebo (improvement)

no effect, p = 0.07

a 1.92-point improvement vs 0.34-point improvement in the placebo arm (p = 0.07) at week 16

PMID 21502597 · one of two readings recorded this

clinical global impression of change

no effect

Changes in clinical global impression of change, NPI, and activities of daily living were not significant at either dose

PMID 21502597 · one of two readings recorded this

Neuropsychiatric Inventory (NPI)

no effect

Changes in clinical global impression of change, NPI, and activities of daily living were not significant at either dose

PMID 21502597 · one of two readings recorded this

activities of daily living

unclear, p = 0.01, n = 39

After 12 weeks of treatment, the MMSE, CDR, and ADL scores significantly improved in the Huperzine A group (P < 0.01 for all comparisons)

PMID 21833673 · one of two readings recorded this

activities of daily living

no effect, p = 0.05, n = 39

whereas the placebo group did not show any such improvement (P > 0.05 for all comparisons)

PMID 21833673 · one of two readings recorded this

cognition

increases, p = 0.01, n = 39

After 12 weeks of treatment, the MMSE, CDR, and ADL scores significantly improved in the Huperzine A group (P < 0.01 for all comparisons)

PMID 21833673 · one of two readings recorded this

cognition

no effect, p = 0.05, n = 39

whereas the placebo group did not show any such improvement (P > 0.05 for all comparisons)

PMID 21833673 · one of two readings recorded this

dementia severity

unclear, p = 0.01, n = 39

After 12 weeks of treatment, the MMSE, CDR, and ADL scores significantly improved in the Huperzine A group (P < 0.01 for all comparisons)

PMID 21833673 · one of two readings recorded this

dementia severity

no effect, p = 0.05, n = 39

whereas the placebo group did not show any such improvement (P > 0.05 for all comparisons)

PMID 21833673 · one of two readings recorded this

MMSE, CDR and ADL scores after 12 weeks, huperzine A 0.1 mg bid versus vitamin C 100 mg bid as placebo

increases, significant improvement in the huperzine A group (within-group) while placebo did not improve (within-group); no between-arm test stated, n = 78

Not recorded as a finding: the result compares a group with itself, not with a control

After 12 weeks of treatment, the MMSE, CDR, and ADL scores significantly improved in the Huperzine A group (P < 0.01 for all comparisons), whereas the placebo group did not show any such improvement (P > 0.05 for all comparisons).

PMID 21833673 · one of two readings recorded this

MMSE, CDR and ADL scores over 12 weeks, huperzine A 0.1 mg bid versus vitamin C placebo, vascular dementia

increases, within-group improvement in the Huperzine A group, none in the placebo group; no between-arm test stated

Not recorded as a finding: the result compares a group with itself, not with a control

After 12 weeks of treatment, the MMSE, CDR, and ADL scores significantly improved in the Huperzine A group (P < 0.01 for all comparisons), whereas the placebo group did not show any such improvement (P > 0.05 for all comparisons).

PMID 21833673 · one of two readings recorded this

eligible randomised placebo-controlled trials of huperzine A in MCI

unclear

No eligible trials were identified

PMID 23235666 · one of two readings recorded this

activities of daily living, ADCS-ADL (change from baseline, one trial)

no effect

when measured by Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL), one trial showed no significant change in activities of daily living in Huperzine A group at 16 weeks

PMID 24086396 · one of two readings recorded this

activities of daily living, ADL versus piracetam (last observation scores)

increases

One trial demonstrated Huperzine A had a better effect than Piracetam at 8 weeks

PMID 24086396 · one of two readings recorded this

cognitive function, ADAS-Cog (change from baseline, two trials)

no effect

when measured by Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), two individual trials demonstrated there were no statistical differences between Huperzine A and placebo

PMID 24086396 · one of two readings recorded this

cognitive function, MMSE versus galanthamine hydrobromide, vitamin C or donepezil (last observation scores)

no effect

there were no statistical differences between Huperzine A and Galanthamine hydrobromide, Vitamin C or Donepezil

PMID 24086396 · one of two readings recorded this

cognitive function, MMSE versus piracetam (last observation scores)

increases

as measured by MMSE, Huperzine A resulted in higher scores compared with Piracetam at 8 weeks

PMID 24086396 · one of two readings recorded this

adverse events, number and severity, ANOVA across placebo, huperzine A 0.4 mg and 0.8 mg

no effect, F2,119=.82, p = 0.44

Not recorded as a finding: The sentence names only treatment groups, not huperzine A or a dose, and the node counts the proportion with any adverse event rather than an ANOVA of number and severity

Analyses showed no statistical differences in the number or severity of AEs among treatment groups (F2,119=.82, P=.44).

PMID 26364275 · one of two readings recorded this

cocaine-induced subjective effect ratings on 0-100 visual analogue scales (Any Drug Effect, High, Stimulated, Willing to Pay), huperzine A 0.4 mg versus placebo

decreases, t = 2.66, p = 0.009

Not recorded as a finding: No outcome node for acute cocaine-induced VAS ratings; the effect is a reduction at 0.4 mg but not at 0.8 mg

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=2.66, P=.009), but not HupA 0.8mg vs placebo (t=1.11, P=.27).

PMID 26364275 · one of two readings recorded this

cocaine pharmacokinetic parameters (all), HupA vs placebo

no effect, p = 0.05

In comparison with placebo, treatment with HupA did not cause significant changes in any cocaine PK parameters (all P>.05)

PMID 26364275 · one of two readings recorded this

diastolic blood pressure, day 10, cocaine 20 mg: HupA 0.4 mg vs placebo

no effect, p = 0.26

Exploratory pair-wise comparisons within the 20mg cocaine dose showed no significant effect for HupA 0.4mg vs placebo (t=1.7, P=.26) nor HupA 0.8mg vs placebo (t=.87, P=.63)

PMID 26364275 · one of two readings recorded this

diastolic blood pressure, day 10, cocaine 20 mg: HupA 0.8 mg vs placebo

no effect, p = 0.63

Exploratory pair-wise comparisons within the 20mg cocaine dose showed no significant effect for HupA 0.4mg vs placebo (t=1.7, P=.26) nor HupA 0.8mg vs placebo (t=.87, P=.63)

PMID 26364275 · one of two readings recorded this

heart rate AUC, day 9, cocaine 40 mg: HupA 0.4 mg vs placebo

no effect, p = 0.67

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed no significant differences between placebo vs HupA 0.4mg (t=.42, P=.67) or placebo vs HupA 0.8mg (t=.22, P=.82)

PMID 26364275 · one of two readings recorded this

heart rate AUC, day 9, cocaine 40 mg: HupA 0.8 mg vs placebo

no effect, p = 0.82

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed no significant differences between placebo vs HupA 0.4mg (t=.42, P=.67) or placebo vs HupA 0.8mg (t=.22, P=.82)

PMID 26364275 · one of two readings recorded this

heart rate, day 10, cocaine 20 mg: HupA 0.4 mg vs placebo

decreases, p = 0.01

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=3.1, P=.01), but not HupA 0.8mg vs placebo (t=.54, P=.59)

PMID 26364275 · one of two readings recorded this

heart rate, day 10, cocaine 20 mg: HupA 0.8 mg vs placebo

no effect, p = 0.59

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=3.1, P=.01), but not HupA 0.8mg vs placebo (t=.54, P=.59)

PMID 26364275 · one of two readings recorded this

number and severity of adverse events, huperzine A 0.4 or 0.8 mg versus placebo, with IV cocaine challenge in both arms

no effect, F2,119 = .82, p = 0.44

Not recorded as a finding: The result sentence names the arms only as treatment groups, and the endpoint is a count and severity of events rather than the proportion with at least one event (supplement-adverse-event-incidence node)

Analyses showed no statistical differences in the number or severity of AEs among treatment groups (F2,119=.82, P=.44).

PMID 26364275 · one of two readings recorded this

number of choices for cocaine infusions, day 10, cocaine 20 mg: HupA 0.4 mg vs placebo

no effect, p = 0.097

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed no significant difference between HupA 0.4mg vs placebo (t=1.99, P=.097) nor HupA 0.8mg vs placebo (t=1.15, P=.25)

PMID 26364275 · one of two readings recorded this

number of choices for cocaine infusions, day 10, cocaine 20 mg: HupA 0.8 mg vs placebo

no effect, p = 0.25

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed no significant difference between HupA 0.4mg vs placebo (t=1.99, P=.097) nor HupA 0.8mg vs placebo (t=1.15, P=.25)

PMID 26364275 · one of two readings recorded this

number or severity of adverse events, among HupA 0, 0.4 and 0.8 mg groups

no effect, p = 0.44

Analyses showed no statistical differences in the number or severity of AEs among treatment groups (F2,119=.82, P=.44)

PMID 26364275 · one of two readings recorded this

systolic blood pressure AUC, day 9, cocaine 40 mg: HupA 0.4 mg vs placebo

no effect, p = 0.06

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed no significant differences between placebo vs HupA 0.4mg (t=1.87, P=.06) or placebo vs HupA 0.8mg (t=.75, P=.46)

PMID 26364275 · one of two readings recorded this

systolic blood pressure AUC, day 9, cocaine 40 mg: HupA 0.8 mg vs placebo

no effect, p = 0.46

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed no significant differences between placebo vs HupA 0.4mg (t=1.87, P=.06) or placebo vs HupA 0.8mg (t=.75, P=.46)

PMID 26364275 · one of two readings recorded this

systolic blood pressure, day 10, cocaine 20 mg: HupA 0.4 mg vs placebo

no effect, p = 0.07

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed no significant effect for HupA 0.4mg vs placebo (t=2.3, P=.07) nor HupA 0.8mg vs placebo (t=.30, P=.76)

PMID 26364275 · one of two readings recorded this

systolic blood pressure, day 10, cocaine 20 mg: HupA 0.8 mg vs placebo

no effect, p = 0.76

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed no significant effect for HupA 0.4mg vs placebo (t=2.3, P=.07) nor HupA 0.8mg vs placebo (t=.30, P=.76)

PMID 26364275 · one of two readings recorded this

VAS Any Drug Effect AUC, day 9, cocaine 40 mg: HupA 0.4 mg vs placebo

decreases, p = 0.009

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=2.66, P=.009), but not HupA 0.8mg vs placebo (t=1.11, P=.27)

PMID 26364275 · one of two readings recorded this

VAS Any Drug Effect AUC, day 9, cocaine 40 mg: HupA 0.8 mg vs placebo

no effect, p = 0.27

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=2.66, P=.009), but not HupA 0.8mg vs placebo (t=1.11, P=.27)

PMID 26364275 · one of two readings recorded this

VAS Any Drug Effect, day 10, cocaine 20 mg: HupA 0.4 mg vs placebo

decreases, p = 0.0002

Pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=3.48, P=.0002), but not HupA 0.8mg vs placebo (t=1.61, P=.11)

PMID 26364275 · one of two readings recorded this

VAS Any Drug Effect, day 10, cocaine 20 mg: HupA 0.8 mg vs placebo

no effect, p = 0.11

Pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=3.48, P=.0002), but not HupA 0.8mg vs placebo (t=1.61, P=.11)

PMID 26364275 · one of two readings recorded this

VAS High, day 10, cocaine 20 mg: HupA 0.4 mg vs placebo

decreases, p = 0.0004

Pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=3.31, P=.0004), but not HupA 0.8mg vs placebo (t=1.23, P=.22)

PMID 26364275 · one of two readings recorded this

VAS High, day 10, cocaine 20 mg: HupA 0.8 mg vs placebo

no effect, p = 0.22

Pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=3.31, P=.0004), but not HupA 0.8mg vs placebo (t=1.23, P=.22)

PMID 26364275 · one of two readings recorded this

VAS Likely to Use if Given Access, day 10, cocaine 20 mg: HupA 0.4 mg vs placebo

decreases, p = 0.027

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=2.66, P=.027), but not HupA 0.8mg vs placebo (t=1.14, P=.26)

PMID 26364275 · one of two readings recorded this

VAS Likely to Use if Given Access, day 10, cocaine 20 mg: HupA 0.8 mg vs placebo

no effect, p = 0.26

Exploratory pair-wise comparisons within the 20-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=2.66, P=.027), but not HupA 0.8mg vs placebo (t=1.14, P=.26)

PMID 26364275 · one of two readings recorded this

VAS Stimulated AUC, day 9, cocaine 40 mg: HupA 0.4 mg vs placebo

decreases, p = 0.015

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=2.47, P=.015) and a significant reduction of effect for HupA 0.8mg vs placebo (t=2.15, P=.034)

PMID 26364275 · one of two readings recorded this

VAS Stimulated AUC, day 9, cocaine 40 mg: HupA 0.8 mg vs placebo

decreases, p = 0.034

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=2.47, P=.015) and a significant reduction of effect for HupA 0.8mg vs placebo (t=2.15, P=.034)

PMID 26364275 · one of two readings recorded this

VAS Willing to Pay AUC, day 9, cocaine 40 mg: HupA 0.4 mg vs placebo

decreases, p = 0.05

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=1.96, P=.05), but not HupA 0.8mg vs placebo (t=.60, P=.55)

PMID 26364275 · one of two readings recorded this

VAS Willing to Pay AUC, day 9, cocaine 40 mg: HupA 0.8 mg vs placebo

no effect, p = 0.55

Exploratory pair-wise comparisons within the 40-mg cocaine dose showed a significant reduction of effect for HupA 0.4mg vs placebo (t=1.96, P=.05), but not HupA 0.8mg vs placebo (t=.60, P=.55)

PMID 26364275 · one of two readings recorded this

all-cause discontinuation (HupA versus comparators)

no effect, p = 0.2

All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p = 0.20)

PMID 27302211 · one of two readings recorded this

memory quotient, Wechsler Memory Scale-Revised (HupA versus comparators)

increases, p = 0.0001

Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p < 0.0001)

PMID 27302211 · one of two readings recorded this

psychopathology total score, PANSS (n = 7) or BPRS (n = 1) (HupA versus comparators)

decreases, p = 0.002

the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p = 0.002)

PMID 27302211 · one of two readings recorded this

response administer and non-perseverative errors, Wisconsin Card Sorting Test (HupA versus comparators, ranges reported)

decreases

Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p = 0.03 to 0.003)

PMID 27302211 · one of two readings recorded this

verbal IQ, performance IQ and full IQ, Wechsler Adult Intelligence Scale-Revised (HupA versus comparators, ranges reported)

increases

Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p = 0.01 to 0.00001)

PMID 27302211 · one of two readings recorded this

bioequivalence, AUC0-72h

no effect

The 90% confidence intervals for the AUC0-72h and Cmax were between 0.80 and 1.25

PMID 29058298 · one of two readings recorded this

bioequivalence, Cmax

no effect

The 90% confidence intervals for the AUC0-72h and Cmax were between 0.80 and 1.25

PMID 29058298 · one of two readings recorded this

huperzine A plasma Cmax, t1/2 and AUC0-72h, and bioequivalence of two test formulations against a reference huperzine A formulation

no effect, 90% CIs for AUC0-72h and Cmax between 0.80 and 1.25

Not recorded as a finding: the comparison was against another active treatment

The 90% confidence intervals for the AUC0-72h and Cmax were between 0.80 and 1.25.

PMID 29058298 · one of two readings recorded this

huperzine A plasma Cmax, t1/2 and AUC0-72h by LC-MS/MS, two test formulations versus a reference formulation, bioequivalence crossover

no effect, 90% CIs for AUC0-72h and Cmax between 0.80 and 1.25

Not recorded as a finding: the comparison was against another active treatment

The 90% confidence intervals for the AUC0-72h and Cmax were between 0.80 and 1.25.

PMID 29058298 · one of two readings recorded this

Mini-Mental State Examination (MMSE) change, huperzine-A versus control group (CG), Bayesian network meta-analysis

increases

Not recorded as a finding: the supporting sentence never names the compound

Our analysis revealed that memantine, galantamine, huperizine-A, and rivastigmine had significantly greater improvement than CG (Table 2).

PMID 30425461 · one of two readings recorded this

MMSE change from baseline, Bayesian network meta-analysis of six cognitive drugs against control groups

increases

Not recorded as a finding: the supporting sentence never names the compound

Our analysis revealed that memantine, galantamine, huperizine-A, and rivastigmine had significantly greater improvement than CG (Table 2).

PMID 30425461 · one of two readings recorded this

MMSE improvement versus control group (network meta-analysis)

increases

memantine, galantamine, huperizine-A, and rivastigmine had significantly greater improvement than CG

PMID 30425461 · one of two readings recorded this

MMSE improvement versus control group (network meta-analysis)

increases

memantine, galantamine, huperizine-A, and rivastigmine had significantly greater improvement than CG

PMID 30425461 · one of two readings recorded this

MMSE improvement versus control group (network meta-analysis)

increases

memantine, galantamine, huperizine-A, and rivastigmine had significantly greater improvement than CG

PMID 30425461 · one of two readings recorded this

MMSE improvement versus control group (network meta-analysis)

increases

memantine, galantamine, huperizine-A, and rivastigmine had significantly greater improvement than CG

PMID 30425461 · one of two readings recorded this

MMSE, SUCRA ranking

donepezil seemed to have the lowest probability (SUCRA=43.4%)

PMID 30425461 · one of two readings recorded this

MMSE, SUCRA ranking

followed by galantamine (SUCRA=65.4%), huperizine-A (SUCRA=53.3%), rivastigmine (SUCRA=52.1%), and tacrine (SUCRA=44.9%)

PMID 30425461 · one of two readings recorded this

MMSE, SUCRA ranking

followed by galantamine (SUCRA=65.4%), huperizine-A (SUCRA=53.3%), rivastigmine (SUCRA=52.1%), and tacrine (SUCRA=44.9%)

PMID 30425461 · one of two readings recorded this

MMSE, SUCRA ranking

memantine was the highest in probability among all the six cognitive drugs (SUCRA=70.5%)

PMID 30425461 · one of two readings recorded this

MMSE, SUCRA ranking

followed by galantamine (SUCRA=65.4%), huperizine-A (SUCRA=53.3%), rivastigmine (SUCRA=52.1%), and tacrine (SUCRA=44.9%)

PMID 30425461 · one of two readings recorded this

MMSE, SUCRA ranking

followed by galantamine (SUCRA=65.4%), huperizine-A (SUCRA=53.3%), rivastigmine (SUCRA=52.1%), and tacrine (SUCRA=44.9%)

PMID 30425461 · one of two readings recorded this

cognition (Addenbrooke's Cognitive Examination)

increases

There was significant improvement in cognition and task switching abilities post Huperzine-A treatment compared with baseline performance

PMID 30839402 · one of two readings recorded this

cognition and task switching, AD patients versus healthy individuals at baseline

decreases

Patients with AD showed cognitive and task switching deficits in contrast with healthy individuals

PMID 30839402 · one of two readings recorded this

cognition on Addenbrooke's Cognitive Examination and task switching on the Trail Making Test, before and after eight weeks of Huperzine-A in Alzheimer's disease

increases, significant improvement versus the patients' own baseline

Not recorded as a finding: the result compares a group with itself, not with a control

There was significant improvement in cognition and task switching abilities post Huperzine-A treatment compared with baseline performance.

PMID 30839402 · one of two readings recorded this

cognition on Addenbrooke's Cognitive Examination and task switching on Trail Making Test, baseline versus after eight weeks of huperzine-A

increases, improvement versus baseline performance; no estimate stated, n = 50

Not recorded as a finding: the result compares a group with itself, not with a control

There was significant improvement in cognition and task switching abilities post Huperzine-A treatment compared with baseline performance.

PMID 30839402 · one of two readings recorded this

task switching (Trail Making Test)

increases

There was significant improvement in cognition and task switching abilities post Huperzine-A treatment compared with baseline performance

PMID 30839402 · one of two readings recorded this

cognitive scores, oral tablet versus capsule

no effect

there was no statistical difference between oral tablet and capsule

PMID 30989926 · one of two readings recorded this

memory quotient (MQ), huperzine A versus placebo

increases

Not recorded as a finding: No outcome node for memory quotient; instrument not named in the abstract

Compared with placebo, huperzine A was superior in the scores of MQ and MMSE.

PMID 30989926 · one of two readings recorded this

memory quotient, MQ (huperzine versus placebo)

increases

compared with placebo, Huperzine significantly increased the scores of memory quotient(MQ) and mini-mental state examination(MMSE)

PMID 30989926 · one of two readings recorded this

memory quotient (MQ), instrument not named in the abstract

increases

Not recorded as a finding: No outcome node for memory quotient

The Meta-analysis results showed that compared with placebo, Huperzine significantly increased the scores of memory quotient(MQ) and mini-mental state examination(MMSE).

PMID 30989926 · one of two readings recorded this

mini-mental state examination, MMSE (huperzine versus placebo)

increases

compared with placebo, Huperzine significantly increased the scores of memory quotient(MQ) and mini-mental state examination(MMSE)

PMID 30989926 · one of two readings recorded this

cognitive impairment, donepezil versus memantine

increases

In the subgroup of severe cognitive impairment, donepezil induced greater relief of severe cognitive impairment in patients with AD than did memantine

PMID 31277107 · one of two readings recorded this

Mini-Mental State Examination (MMSE) score in a network meta-analysis of anti-dementia drugs, reported separately for mild, moderate and severe cognitive impairment subgroups

huperzine A MD 2.4 in the mild subgroup

Not recorded as a finding: every result is a subgroup, with no whole-population estimate

The results show that, in the subgroup of patients with mild cognitive impairment, the most effective of the 12 drugs administered were donepezil, galantamine, and huperzine A: the mean-difference values were 5.2, 2.5, and 2.4, respectively.

PMID 31277107 · one of two readings recorded this

MMSE mean difference, mild cognitive impairment subgroup

increases

The results show that, in the subgroup of patients with mild cognitive impairment, the most effective of the 12 drugs administered were donepezil, galantamine, and huperzine A: the mean-difference values were 5.2, 2.5, and 2.4, respectively

PMID 31277107 · one of two readings recorded this

MMSE mean difference, mild cognitive impairment subgroup

increases

The results show that, in the subgroup of patients with mild cognitive impairment, the most effective of the 12 drugs administered were donepezil, galantamine, and huperzine A: the mean-difference values were 5.2, 2.5, and 2.4, respectively

PMID 31277107 · one of two readings recorded this

MMSE mean difference, mild cognitive impairment subgroup

increases

The results show that, in the subgroup of patients with mild cognitive impairment, the most effective of the 12 drugs administered were donepezil, galantamine, and huperzine A: the mean-difference values were 5.2, 2.5, and 2.4, respectively

PMID 31277107 · one of two readings recorded this

MMSE mean difference, moderate cognitive impairment subgroup

increases

In the moderate cognitive impairment subgroups, the most efficacious drugs were found to be donepezil, huperzine A, and rivastigmine: the mean-difference values were 3.8, 2.9, and 3.0, respectively

PMID 31277107 · one of two readings recorded this

MMSE mean difference, moderate cognitive impairment subgroup

increases

In the moderate cognitive impairment subgroups, the most efficacious drugs were found to be donepezil, huperzine A, and rivastigmine: the mean-difference values were 3.8, 2.9, and 3.0, respectively

PMID 31277107 · one of two readings recorded this

MMSE mean difference, moderate cognitive impairment subgroup

increases

In the moderate cognitive impairment subgroups, the most efficacious drugs were found to be donepezil, huperzine A, and rivastigmine: the mean-difference values were 3.8, 2.9, and 3.0, respectively

PMID 31277107 · one of two readings recorded this

MMSE total score, network meta-analysis, mild and moderate AD subgroups

increases

Not recorded as a finding: the supporting sentence never names the compound

The results show that, in the subgroup of patients with mild cognitive impairment, the most effective of the 12 drugs administered were donepezil, galantamine, and huperzine A: the mean-difference values were 5.2, 2.5, and 2.4, respectively.

PMID 31277107 · one of two readings recorded this

depression, within-arm improvement in both groups

decreases

Both groups showed clinically important improvements in depression on the Beck Depression Index

PMID 31638455 · one of two readings recorded this

learning and memory scores, within-arm change

increases

In the placebo group, significant improvements were noted in learning and memory scores

PMID 31638455 · one of two readings recorded this

memory and learning on the California Verbal Learning Test, 2nd Edition (CVLT-II), baseline to week 12

no effect

Not recorded as a finding: this platform holds no node for the endpoint

There was no difference between the Huperzine A and placebo groups in memory performance after 12 weeks of treatment.

PMID 31638455 · one of two readings recorded this

memory and learning on the California Verbal Learning Test, 2nd Edition (CVLT-II), change from baseline to week 12

no effect

Not recorded as a finding: this platform holds no node for the endpoint

There was no difference between the Huperzine A and placebo groups in memory performance after 12 weeks of treatment.

PMID 31638455 · one of two readings recorded this

memory performance, change from baseline to week 12

no effect

There was no difference between the Huperzine A and placebo groups in memory performance after 12 weeks of treatment

PMID 31638455 · one of two readings recorded this

acceptability (treatment completion), network meta-analysis versus placebo

unclear

galantamine 24 mg (OR = 0.72, 95% CrI: [0.53, 0.95])

PMID 32528296 · one of two readings recorded this

acceptability (treatment completion), network meta-analysis versus placebo

unclear

galantamine 32 mg (OR = 0.44, 95% CrI: [0.27, 0.71])

PMID 32528296 · one of two readings recorded this

acceptability (treatment completion), network meta-analysis versus placebo

unclear

rivastigmine 10 cm2 patch (OR = 0.60, 95% CrI: [0.37, 0.95])

PMID 32528296 · one of two readings recorded this

acceptability (treatment completion), network meta-analysis versus placebo

unclear

rivastigmine 12 mg (OR = 0.52, 95% CrI: [0.34, 0.79])

PMID 32528296 · one of two readings recorded this

ADCS-ADL, network meta-analysis versus placebo

increases

0.21 (0.02, 0.40) for donepezil 10 mg

PMID 32528296 · one of two readings recorded this

ADCS-ADL, network meta-analysis versus placebo

increases

0.22 (0.06, 0.37) for galantamine 24 mg

PMID 32528296 · one of two readings recorded this

ADCS-ADL, network meta-analysis versus placebo

increases

0.51 (0.17, 0.81) for the rivastigmine 15 cm2 patch

PMID 32528296 · one of two readings recorded this

any adverse event, network meta-analysis versus placebo

increases

OR = 1.43, 95% CrI: [1.16, 1.76]

PMID 32528296 · one of two readings recorded this

any adverse event, network meta-analysis versus placebo

decreases

only EGb761 240 mg was better tolerated than placebo for safety (OR = 0.66, 95% CrI: [0.43, 0.99])

PMID 32528296 · one of two readings recorded this

any adverse event, network meta-analysis versus placebo

increases

OR = 1.53, 95% CrI: [1.25, 1.98]

PMID 32528296 · one of two readings recorded this

any adverse event, network meta-analysis versus placebo

increases

OR = 2.51, 95% CrI: [1.58, 4.09]

PMID 32528296 · one of two readings recorded this

any adverse event, network meta-analysis versus placebo

increases

OR = 1.68, 95% CrI: [1.18, 2.48]

PMID 32528296 · one of two readings recorded this

any adverse event, network meta-analysis versus placebo

increases

OR = 2.69, 95% CrI: [1.96, 3.90]

PMID 32528296 · one of two readings recorded this

any adverse event, network meta-analysis versus placebo

increases

OR = 2.34, 95% CrI: [1.19, 4.83]

PMID 32528296 · one of two readings recorded this

clinical global impression (CIBIC-plus), network meta-analysis versus placebo

increases

SMD = −0.34, 95% CrI: [−0.50, −0.17]

PMID 32528296 · one of two readings recorded this

clinical global impression (CIBIC-plus), network meta-analysis versus placebo

increases

SMD = −0.29, 95% CrI: [−0.53, −0.06]

PMID 32528296 · one of two readings recorded this

clinical global impression (CIBIC-plus), network meta-analysis versus placebo

increases

SMD = −0.27, 95% CrI: [−0.48, −0.07]

PMID 32528296 · one of two readings recorded this

clinical global impression (CIBIC-plus), network meta-analysis versus placebo

increases

SMD = −0.40, 95% CrI: [−0.62, −0.18]

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), network meta-analysis versus placebo

increases

−0.30 (−0.52, −0.07) for donepezil 10 mg

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), network meta-analysis versus placebo

increases

and −0.37 (−0.69, −0.04) for donepezil 5 mg

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), network meta-analysis versus placebo

increases

SMDs of −0.39 (95% CrI: [−0.65, −0.12]) for galantamine 24 mg

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), network meta-analysis versus placebo

increases

−0.62 (−1.01, −0.24) for galantamine 32 mg

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), pair-wise versus placebo

no effect

The tested interventions, except for rivastigmine 12 mg, the rivastigmine 5 cm2 patch, huperzine A 400 µg, and huperzine A 200 µg, showed statistically significant differences with regard to the ADCS-cog assessment

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), pair-wise versus placebo

no effect

The tested interventions, except for rivastigmine 12 mg, the rivastigmine 5 cm2 patch, huperzine A 400 µg, and huperzine A 200 µg, showed statistically significant differences with regard to the ADCS-cog assessment

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), SUCRA ranking

galantamine 32 mg (SUCRA = 93.2%), galantamine 24 mg (SUCRA = 75.5%), donepezil 5 mg (SUCRA = 73.3%), donepezil 10 mg (SUCRA = 65.6%), and memantine 20 mg (SUCRA = 57.0%)

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), SUCRA ranking

galantamine 32 mg (SUCRA = 93.2%), galantamine 24 mg (SUCRA = 75.5%), donepezil 5 mg (SUCRA = 73.3%), donepezil 10 mg (SUCRA = 65.6%), and memantine 20 mg (SUCRA = 57.0%)

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), SUCRA ranking

galantamine 32 mg (SUCRA = 93.2%), galantamine 24 mg (SUCRA = 75.5%), donepezil 5 mg (SUCRA = 73.3%), donepezil 10 mg (SUCRA = 65.6%), and memantine 20 mg (SUCRA = 57.0%)

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), SUCRA ranking

galantamine 32 mg (SUCRA = 93.2%), galantamine 24 mg (SUCRA = 75.5%), donepezil 5 mg (SUCRA = 73.3%), donepezil 10 mg (SUCRA = 65.6%), and memantine 20 mg (SUCRA = 57.0%)

PMID 32528296 · one of two readings recorded this

cognitive function (ADAS-cog), SUCRA ranking

galantamine 32 mg (SUCRA = 93.2%), galantamine 24 mg (SUCRA = 75.5%), donepezil 5 mg (SUCRA = 73.3%), donepezil 10 mg (SUCRA = 65.6%), and memantine 20 mg (SUCRA = 57.0%)

PMID 32528296 · one of two readings recorded this

MMSE, network meta-analysis versus placebo

no effect

In the network meta-analysis, no interventions were associated with statistically significant differences compared with placebo

PMID 32528296 · one of two readings recorded this

MMSE, network meta-analysis versus placebo

no effect

In the network meta-analysis, no interventions were associated with statistically significant differences compared with placebo

PMID 32528296 · one of two readings recorded this

MMSE, pair-wise versus placebo

increases

in the MMSE, donepezil 10 mg, donepezil 5 mg, rivastigmine 10 cm2, galantamine 24 mg, huperzine A 400 µg, and huperzine A 200 µg was superior to the placebo

PMID 32528296 · one of two readings recorded this

MMSE, pair-wise versus placebo

increases

in the MMSE, donepezil 10 mg, donepezil 5 mg, rivastigmine 10 cm2, galantamine 24 mg, huperzine A 400 µg, and huperzine A 200 µg was superior to the placebo

PMID 32528296 · one of two readings recorded this

ADL score, comparative efficacy ranking (SUCRA)

increases

Butylphthalide | 90.32 | HuperzineA | 82.15 | Co-dergocrine Mesyiate | 99.61

PMID 39239652 · one of two readings recorded this

ADL score, Huperzine A versus Piracetam, Oxiracetam, Xuesaitong and Placebo

increases

Huperzine A demonstrated superior effectiveness in improving ADL scores compared to other treatments, including Piracetam, Oxiracetam, Xuesaitong, and Placebo

PMID 39239652 · one of two readings recorded this

adverse effects rate, safety ranking (SUCRA)

unclear

Huperzine A | 8.62

PMID 39239652 · one of two readings recorded this

MMSE score, comparative efficacy ranking (SUCRA)

increases

HuperzineA | 88.11 | Butylphthalide | 79.62 | Tongxinluo capsule | 82.07

PMID 39239652 · one of two readings recorded this

MMSE score, huperzine A versus donepezil

increases

Not recorded as a finding: Comparator is an active drug, not absence of the compound; the placebo contrast for MMSE is not stated in words

In terms of MMSE scores, Huperzine A demonstrates superior efficacy compared to Donepezil, while Nimodipine and Xuesaitong exhibits inferior efficacy.

PMID 39239652 · one of two readings recorded this

MMSE score, Huperzine A versus Donepezil

increases

In terms of MMSE scores, Huperzine A demonstrates superior efficacy compared to Donepezil

PMID 39239652 · one of two readings recorded this

behavioral function

increases, p = 0.01

About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions

PMID 8701750 · one of two readings recorded this

cognitive function

increases, p = 0.01

About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions

PMID 8701750 · one of two readings recorded this

memory function

increases, p = 0.01

About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions

PMID 8701750 · one of two readings recorded this

overall efficacy (proportion improved in memory, cognition and behaviour) on Wechsler memory scale, Hasegawa dementia scale, MMSE and ADL, huperzine-A tablets 0.2 mg bid versus placebo for 8 weeks

increases, efficacy better than placebo (36%, 19/53), n = 103

Not recorded as a finding: the paper never states the instrument the node requires

The efficacy of Hup was better than placebo (36%, 19/53) (P < 0.05).

PMID 8701750 · one of two readings recorded this

proportion of Alzheimer patients improved in memory, cognition and behaviour (Wechsler memory scale, Hasegawa dementia scale, MMSE, ADL), huperzine-A 0.2 mg bid tablets versus placebo for 8 weeks

increases

Not recorded as a finding: the paper never states the instrument the node requires

The efficacy of Hup was better than placebo (36%, 19/53) (P < 0.05).

PMID 8701750 · one of two readings recorded this

proportion of patients improved, Hup versus placebo

increases, p = 0.05

The efficacy of Hup was better than placebo (36%, 19/53) (P < 0.05)

PMID 8701750 · one of two readings recorded this

proportion of patients improved

increases, n = 50

About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions

PMID 8701750 · one of two readings recorded this